· Pharma · Pharma Desk
Late-phase data show patients switching from injectable incretins to oral orforglipron (Foundayo) or lower-dose Zepbound maintain weight loss — a step-down maintenance thesis that expands TAM and defends franchise longevity against Novo's oral semaglutide.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.